Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNancy L. BartlettBoston UniversityMDMichael DickinsonThe Royal Melbourne HospitalMHMartin HutchingsCopenhagen University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bartlett et al. (2024) studied this question.

synapsesocial.com/papers/68e67069b6db6435875fb29ahttps://doi.org/10.1200/jco.2024.42.16_suppl.7020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.2024 · 16 citations
  2. 2Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial2021 · 437 citations
  3. 3Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.2026
  4. 4Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study2024 · 72 citations
  5. 5Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma2025